Johnson & Johnson vs. SCYNEXIS, Inc.
Johnson & Johnson (JNJ) comes out ahead, leading on 6 of 9 compared factors.
Size & Scale
| JNJ | SCYX | |
|---|---|---|
| Market Cap | $650.65 billion | $44.38 million |
| Revenue (TTM) | $97.93 billion | $19.21 million |
| Net Income (TTM) | $21.04 billion | $-10,235,000 |
JNJ leads on 3 of 3 size & scale factors.
Valuation
| JNJ | SCYX | |
|---|---|---|
| P/E Ratio | 31.32 | 14.86 |
| Price / Book | 7.66 | 0.66 |
| Price / Sales | 6.64 | 2.31 |
SCYX leads on 3 of 3 valuation factors.
Profitability
| JNJ | SCYX | |
|---|---|---|
| Net Margin | 21.48% | -53.27% |
| Return on Equity | 24.76% | -15.29% |
JNJ leads on 2 of 2 profitability factors.
Dividend
| JNJ | SCYX | |
|---|---|---|
| Dividend Yield | 1.99% | — |
| Payout Ratio | 62.18 | — |
JNJ and SCYX split the dividend factors evenly.
Risk & Sentiment
| JNJ | SCYX | |
|---|---|---|
| Short Interest | 0.67% | 13.22% |
JNJ leads on 1 of 1 risk & sentiment factors.
Dig deeper: JNJ overview, JNJ financials, SCYX overview, SCYX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.